This section of the website is for patients who have been prescribed Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) in Ireland. Information for members of the general public can be found here.
Side effects reporting information is available at the bottom of this webpage.
This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for an Irish audience
Learn how Dysport® works, its approved uses in adults and children, and what to expect from treatment.
DYS-IE-000968 | August 2025
Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.
Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.
